US 11,774,451 B2
Molecular vibrational spectroscopic markers for detection of cancer
Derek Holman, Redwood City, CA (US); and Francis G. Blankenberg, Portola Valley, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed on Nov. 11, 2020, as Appl. No. 17/95,304.
Claims priority of provisional application 62/938,564, filed on Nov. 21, 2019.
Prior Publication US 2021/0156862 A1, May 27, 2021
Int. Cl. C12N 15/10 (2006.01); B01L 3/00 (2006.01); G01N 21/3504 (2014.01); G01N 33/00 (2006.01); G01N 33/574 (2006.01); G01N 21/64 (2006.01); A61K 45/06 (2006.01); G01N 21/35 (2014.01)
CPC G01N 33/57449 (2013.01) [A61K 45/06 (2013.01); G01N 21/6486 (2013.01); G01N 2021/3595 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A method for determining the presence of one or more cancer biomarkers in a sample, the method comprising:
obtaining a biological sample comprising extracellular vesicles from a patient suspected of having cancer;
dispersing intact extracellular vesicles on a substrate;
recording mid-infrared spectra with single-vesicle resolution of individual cancer-derived extracellular vesicles, or individual subpopulations of cancer-derived extracellular vesicles in the biological sample to determine if a cancer biomarker is present; using mid-infrared vibrational spectroscopy performed with a narrow-band mid-infrared light source or a broadband mid-infrared light source, selected from a (i) synchrotron source including synchrotron infrared nanospectroscopy (SINS) and (ii) atomic force microscope Fourier transform infrared (AFM-FTIR) spectrometer.